120 likes | 127 Views
https://sars-cov-2.creative-biolabs.com/protease-inhibitors-for-the-treatment-of-sars-cov2.htm<br>To help accelerate the development of anti-SARS-CoV-2 therapeutics, Creative Biolabs can provide protease assays to evaluate inhibitors of SARS-CoV-2 proteases
E N D
SARS-CoV-2OutbreakProcess January, 2020 - Named 2019-nCoV February11,2020- NamedSARS-CoV-2 Endof2019-Wuhan,China January30, 2020-PHEIC Now–Spreadinover200countries(WHO)
The SARS-CoV-2 virus that causes COVID-19 belongs to the Coronaviridaefamily. CoronavirusesFamily Birdsand Mammals Mammals SARS-CoV-2
SpikeGlycoprotein(S) Getthevirusintothecell M-Protein Virusgerminationand envelopeformation SARS-CoV-2Structure Hemagglutinin-esterase(HE) Mayfacilitatethevirustoinitiallyadsorb thecellmembrane RNAandNProtein N proteinisrelatedto theformationof nucleocapsidinRNAgenome E-Protein Thesmallestandmost mysterious Envelope
1 4 Release Fusion ACE2 SARS-CoV-2LifeCycle 2 Replicate 3 Assembly
SARS-CoV-2TreatmentStrategies 1 2 3 Use existing molecular libraries and databases to screen for molecules that may haveatherapeuticeffectonSARS-CoV-2. Screentheexistingbroad-spectrum antiviraldrugs. Develop specific drugs based on the genomic information and pathological characteristicsof SARS-CoV-2.
3-1.TargettotheHost ObjectofSpecificDrugs • Enhanceimmuneresponse-suchasthe releaseof interferon. • Block the signal pathways requiredforvirusreplication. • Targetviralandcellsurfacereceptor proteins(ACE2).
3-2.TargettoSARS-CoV-2 ObjectofSpecificDrugs • Block the virus’s binding to human cell receptors or inhibiting the virus’self-assemblyprocess-target tothestructural proteinsofthevirus. • PreventviralRNAsynthesis -target to thegeneticmaterialofthevirus. • Inhibitvirusreplication-target to keyenzymesofthevirus.
① ② Monoclonal antibody/convalescent plasma for ACE2: Preventthevirusintothehostcell. 1 Camostatmesylate:PreventSARS-CoV-2intothecell byactingonTMPRSS2. 2 SARS-CoV-2TreatmentStrategies ③ Lopinavir-Ritonavir: Inhibition of protease activity of SARS-CoV-2. 3 4 Ribavirin-MayinhibitmRNAcapping. ④ RNA Synthesis Inhibitors: Inhibits SARS-CoV-2 RNA synthesisand replication. 5 RNASynthesis Inhibitors ⑤ NeuraminidaseInhibitors(NAIs)-Interferewiththe release of progeny influenza virus from infected host cells. 6 6 science.sciencemag.org/content/367/6485/1412 NAIs Ⓐ
InVitroDiagnostic(IVD) Development • Antibody& ImmunoassayDevelopmentServices • Molecular DiagnosticAssayDevelopment Services • SARS-CoV-2Related Detection Kits CreativeBiolabs’SARS-CoV-2Services • DrugDiscoveryServices • Anti-SARS-CoV-2DrugDiscovery • SARS-CoV-2VaccineDiscovery • SARS-CoV-2 Preclinical Research
SARS-CoV-2 MERS-CoV SARS-CoV CreativeBiolabs’SARS-CoV-2Products Antibody RecombinantProteins Plasmids PCRPrimers&Probes Detection Kits Antibody RecombinantProteins Plasmids ProteinExpressionProducts Antibody RecombinantProteins Plasmids ProteinExpressionProducts OtherCoronavirus RNAExtractionKit KeyReceptorACE2 Antibody RecombinantProteins Plasmids ProteinExpressionProducts Antibody RecombinantProteins Plasmids ProteinExpressionProducts RNAExtractionKits
Web: www.creative-biolabs.com ContactUs Email:info@creative-biolabs.com Address:45-1RamseyRoad,Shirley, NY11967,USA